BioVie Inc. Files Amendment to Current Report

TL;DR

BioVie filed an amendment to its 8-K, updating financial statements/exhibits as of Sept 23, 2024.

AI Summary

BioVie Inc. filed an amendment (8-K/A) on September 24, 2024, to its current report originally filed on September 23, 2024. This amendment pertains to financial statements and exhibits, with the earliest event reported being September 23, 2024. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates an update or correction to previously submitted financial information or exhibits, which could be material for investors assessing the company's financial health and disclosures.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, likely for administrative or minor corrective purposes, rather than a significant event.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NanoAntibiotics, Inc. (company) — Former company name
• September 23, 2024 (date) — Date of earliest event reported
• September 24, 2024 (date) — Filing date of amendment

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
• $1.53 — blic offering price to the investors of $1.53 per share (the " Share Offering Price "
• $1.5299 — blic offering price to the investors of $1.5299 per Pre-Funded Warrant, together with c

Filing Documents

• bivi-20240923_8ka.htm (8-K/A) — 30KB
• bivi-20240923_8kaex5z1.htm (EX-5.1) — 21KB
• image_001.jpg (GRAPHIC) — 28KB
• image_002.jpg (GRAPHIC) — 16KB
• 0001520138-24-000313.txt ( ) — 294KB
• bivi-20240923_lab.xml (EX-101.LAB) — 33KB
• bivi-20240923_pre.xml (EX-101.PRE) — 24KB
• bivi-20240923.xsd (EX-101.SCH) — 3KB
• bivi-20240923_8ka_htm.xml (XML) — 5KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1* Form of Pre-Funded Warrant. 4.2* Form of Common Warrant. 4.3* Form of Placement Agent's Warrant Agreement (included in Exhibit 10.1). 5.1 Opinion of Fennemore Craig, P.C. 5.2* Opinion of Reed Smith LLP. 10.1*+ Placement Agent Agreement, dated as of September 23, 2024 by and between the Company and the Placement Agent. 23.1 Consent of Fennamore Craig, P.C. (included in Exhibit 5.1). 23.2 Consent of Reed Smith LLP (included in Exhibit 5.2). 99.1* Press Release dated September 23, 2024. 99.2* Press Release dated September 23, 2024. * Previously filed as an exhibit to the Original 8-K. + Certain portions of this Exhibit have been omitted pursuant to Regulation S-K Item 601(a)(6) promulgated under the Exchange Act. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR